A 66-year-old man with multiple myeloma treated with zoledronic acid, melphalan, and
prednisone after a tooth extraction developed severe osteonecrosis of the mandible that was …

BACKGROUND AND PURPOSE: Bisphosphonates are drugs that decrease bone turnover
by inhibiting osteoclast activity. An association between the use of bisphosphonates and …

Discussion Some of our cases (3 of 9), like many of those described in literature, do not
present predisposing factors. The osteonecrosis may thus be due mainly to the effect of …

Over the past three years, several reports have been published on jaw osteonecrosis
possibly being associated with the administration of bisphosphonates. Bisphosphonates are …

A 54-year-old man with a 3-year history of IgG myeloma, complicated by hypercalcemia,
who was being treated with dexamethasone, lenalidomide, filgrastim, darbepoetin alfa, and …

Bisphosphonates are compounds used in the treatment of various metabolic and malignant
bone diseases. In the last 2 years there has been a significant increase in referrals to the …

3. Setting The overwhelming majority of cases of osteonecrosis of the jaw occurred in
patients with metastatic cancer or multiple myeloma. The first report [1] described three …

To the Editor:—Recent advances in the early detection and medical management of
malignancy have produced increased cure rates, and longer survival despite residual …

Bisphosphonates are nonmetabolized analogues of pyrophosphate that are used for
treating skeletal complications secondary to bone metastases. These drugs are capable of …

The use of bisphosphonates (BPs) has proven effective in the treatment of bone-related
diseases, despite the potential risk of developing osteonecrosis of the jaw (ONJ). So far …